Johnson & Johnson begins battle over $10 billion case linking baby powder to cancer - Courts have rejected J&J’s two previous ...

In a report released yesterday, Shagun Singh Chadha from RBC Capital initiated coverage with a Buy rating on Johnson & Johnson (JNJ – ...

Johnson & Johnson (JNJ) begins on Tuesday its third attempt to push through a multi-billion-dollar settlement relating to ...

Our clients are passing away,” attorney James Onder told US Bankruptcy Judge Christopher Lopez on Tuesday, the start of a ...

Johnson & Johnson and Sanofi said that while the vaccine showed no safety concerns, it did not meet the necessary ...

Johnson & Johnson is considering selling its stroke care unit, Cerenovus, in a potential $1 billion deal as part of its ...

Check Out Our Latest Report on Johnson & Johnson Johnson & Johnson Stock Down 0.7 % NYSE JNJ opened at $156.20 on Friday. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt ...

The fund owned 13,249 shares of the company’s stock after selling 800 shares during the period. Jmac Enterprises LLC’s holdings in Johnson & Johnson were worth $1,916,000 as of its most recent ...

Inc. (Janssen), a Johnson & Johnson company, to develop and commercialize the vaccine candidate. Under the terms of the agreement, both parties agreed to co-fund current and future research and ...

A class action filed today says Kiwis have been deceived for about two decades through the use of phenylephrine in cold and ...

Johnson & Johnson introduces TECNIS PureSee IOL for presbyopia in India, offering high-quality vision and reduced visual ...